Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis

AIDS

Volumn 13, Issue 13, 1999, Pages 1687-1695

  McNaghten, A D ^a,b   Hanson, Debra L ^c   Jones, Jeffery L ^c   Dworkin, Mark S ^c   Ward, John W ^c   Thompson, M ^d   Sorvillo, F ^e   Buskin, S ^f   Thompson, G ^g   Wotring, L ^h   Davidson, A ⁱ   Troxler, S ^j   McNeely, W ^k  

^a Cncl State Terr Epidemiologists   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d AIDS Research Consortium of Atlanta   (United States)

^e Los Angeles County Department of Public Works   (United States)

^f Seattle King Co Dept Pub Hlth H   (United States)

^g TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^h MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

ⁱ Denver Department of Health and Hospitals   (United States)

^j Louisiana Dept Hlth and Hospitals   (United States)

^k Dept of Health and Human Services ^*  (United States)

more..

Author keywords

Antiretroviral; Chemoprophylaxis; Combination therapy; Survival

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DAPSONE; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PENTAMIDINE; PNEUMOCOCCUS VACCINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICAL RECORD; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; STATISTICS; SURVIVAL TIME; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; BACTERIAL VACCINES; CHEMOPREVENTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PNEUMONIA, PNEUMOCOCCAL; PNEUMONIA, PNEUMOCYSTIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE;

EID: 17644445799     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199909100-00012     Document Type: Article

References (51)

1. Centers for Disease Control. Update: trends in AIDS incidence - United States, 1996. MMWR 1997, 46:861-867.
2. Centers for Disease Control. Update: trends in AIDS incidence, deaths, and prevalence - United States, 1996. MMWR 1997, 46:165-173.
3. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996, 276:146-154.
4. Centers for Disease Control and Prevention. Report of the NIH Panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998, 47 (RR-5):1-82.
5. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
6. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996, 334:1011-1017.
7. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
8. Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992, 326:1037-1042.
9. Saah AJ, Hoover DR, He Y, the Multicenter AIDS Cohort Study. Factors influencing survival after AIDS: report from the multicenter AIDS cohort study (MACS). J Aquir Immune Defic Syndr 1994, 7:287-295.
10. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995, 333:751-756.
11. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994, 271:1083-1087.
12. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996, 335:384-391.
13. Moore, RD, Chaisson RE. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS 1995, 9:1337-1342.
14. Horsburgh Jr CR, Metchock B, Gordon SM, Havlik Jr JA, McGowan JE, Thompson III SE. Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease. J Infect Dis 1994, 170:573-577.
15. Ives DV, Davis RB, Currier JS. Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. AIDS 1995, 9:261-266.
16. Chin DP, Reingold AL, Stone EN, et al. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - a prospective study. J Infect Dis 1994, 170:578-584.
17. Campo RE, Campo CE. Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997, 24:1233-1238.
18. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992, 267:1798-1805.
19. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:608-610.
20. SAS Institute, Inc. SAS/STAI User's Guide, Version 6.12. Cary, NC: SAS Institute Inc.; 1989.
21. Andersen PK, Gill RD. Cox's regression model counting process: a large sample study. Ann Stat 1982, 10:1100-1120.
22. Grambsch PM, Therneau IM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrics 1994, 81:515-526.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481, 562-563.
24. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
25. Fischl MA, Richman DD, Greico MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987, 317:185-191.
26. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS clinical trials group. JAMA 1994, 272:437-442.
27. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of acquired immunodeficiency syndrome. N Engl J Med 1991, 324:1412-1416.
28. Hanson DL, Horsburgh Jr CR, Fann SA, Havlik JA, Thompson III SE. Survival prognosis of HIV-infected patients. J Aquir Immune Defic Syndr 1993, 6:624-629.
29. Lundgren JD, Phillips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994, 271:1088-1092.
30. Lemp GF, Payne SF, Neal D, Temelso T, Rutherford GW. Survival trends for patients with AIDS. JAMA 1990, 263:402-406.
31. De Grottola V, Wulfsohn M, Fischl MA, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Aquir Immune Defic Syndr 1993, 6:359-365.
32. Graham NMH, Hoover DR, Park LP, et al. Survival in HIV infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 1996, 124:1031-1038.
33. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
34. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
35. Centers for Disease Control. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons with human immunodeficiency virus: a summary. MMWR 1995, 44 (RR-8):5, 11-12.
36. Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons with human immunodeficiency virus. MMWR 1997, 46(RR-12):4-7, 12-13.
37. Bozette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995, 332:693-699.
38. Jones JL, Hanson DL, Chu SY, et al. Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends. AIDS 1996, 10:1393-1399.
39. Torres RA, Barr M, Thorn M, et al. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med 1993, 95:573-583.
40. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS clinical trials group protocol 021. N Engl J Med 1992, 327:1842-1848.
41. Mayer HB, Rose DN, Cohen S, Gurtman AC, Cheung TW, Szabo S. The effect of Pneumocystis carinii pneumonia prophylaxis regimens on the incidence of bacterial infections in HIV-infected patients. AIDS 1993, 7:1687-1689.
42. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997, 46(RR-8):1-15.
43. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection: epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992, 177:314-324.
44. Friedland GH, Saltzman B, Vileno J, Freeman K, Schrager LK, Klein RS. Survival differences in patients with AIDS. J Aquir Immune Defic Syndr 1991, 4:144-153.
45. Easterbrook PJ, Emami J, Gazzard B. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients. AIDS 1993, 7:959-967.
46. Mocroft A, Youle M, Morcinek J, et al. Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. Br Med J 1997, 314:9-29.
47. Rothenberg R, Woelfel M, Stoneburner R, Milberg J, Parker R, Truman B. Survival with the acquired immunodeficiency syndrome: experience with 5833 cases in New York City. N Engl J Med 1987, 317:1297-1302.
48. Harris JE. Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987. JAMA 1990, 263:397-401.
49. Selik RM, Karon JR, Ward JW. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis 1997, 176:632-636.
50. Torres R, Thorn M, Newlands J, et al. Randomized trial of intermittent dapsone versus aerosolized pentamidine for primary and secondary prophylaxis of Pneumocystis carinii pneumonia (PCP). VI International Conference on AIDS. San Francisco, June 1990 [abstract ThB407].
51. Chaisson RE, Keruly J, Richman DD, Moore RD. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine: the zidovudine epidemiology group. Arch Intern Med 1992, 152:2009-2013.